An exploratory aim to prospectively determine the frequency of circulating tumor cell-free DNA (ctDNA) detection of ALK and acquired mutations at study entry and with each disease evaluation was performed and will be reported separately (Berko, et al., Nat. Comm. This evidence concerns the gene ALK and neoplasm.